Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03467542 · ClinicalTrials.gov registry record · NA
PHIL in the Treatment of Intracranial dAVF.
A NA study of Arteriovenous Dural Fistula, sponsored by Microvention-Terumo.
- Completed
- Registry status
- NA
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT03467542: Completed NA study of Arteriovenous Dural Fistula, sponsored by Microvention-Terumo.
NCT03467542 is a NA study of Arteriovenous Dural Fistula that has completed, run by Microvention-Terumo. The registered enrollment target is 64 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03467542, a NA study of Arteriovenous Dural Fistula, has completed, sponsored by Microvention-Terumo.
- COMPLETED
- Registry status
- NA
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a prospective, multicenter, single-arm study. Patients with Dural Arteriovenous Fistulas (dAVF) have a few choice for safe treatment. In this study, all patients with qualifying dAVFs will be treated with PHIL® Liquid Embolic material.
Primary Outcome
Reported incidences of death or ipsilateral stroke
Conditions Studied
Interventions
- DEVICE PHIL® Liquid Embolic System
Study Locations (1)
New York
- Albany Medical Center - Albany
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2018-08-24 |
| Est. Completion | 2022-12-12 |
| Phase | NA |
What the finished NCT03467542 record still lists
NCT03467542 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Arteriovenous Dural Fistula appearing as the primary indexed condition, and to 1 intervention - of which PHIL® Liquid Embolic System is the first listed.
NCT03467542 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03467542 about?
NCT03467542 is a clinical study titled "PHIL in the Treatment of Intracranial dAVF.". This study is a prospective, multicenter, single-arm study. Patients with Dural Arteriovenous Fistulas (dAVF) have a few choice for safe treatment. In this study, all patients with qualifying dAVFs will be treated with PHIL® Liquid Embolic material.
What is the current status of trial NCT03467542?
This trial is currently completed. It is a NA study. The enrollment target is 64 participants. The study started on 2018-08-24. Estimated completion is 2022-12-12.
What conditions does trial NCT03467542 study?
This clinical trial studies the following conditions: Arteriovenous Dural Fistula.
What interventions are being tested in trial NCT03467542?
The interventions under investigation include: PHIL® Liquid Embolic System (DEVICE).
Who is sponsoring clinical trial NCT03467542?
This trial is sponsored by Microvention-Terumo, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03467542 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03467542's enrollment target sits among peer trials
64 1147th of 2000 higher than 844 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI